FDA accepts ev3's PMA filing
This article was originally published in Clinica
Executive Summary
The US FDA has accepted ev3's premarket approval (PMA) application for its Pipeline Embolization Device, intended for the treatment of large, giant and wide-necked cerebral aneurysms. The PMA application will receive expedited review and processing. The filing is supported by data from the 108-patient PUFS (Pipeline for Uncoilable or Failed AneurysmS) study. Plymouth, Minnesota-based ev3 estimates that the potential market for the device could reach $350m in 2013.